UIM
ALXN

USS Investment Management’s Alexion Pharmaceuticals ALXN Stock Holding History

USS Investment Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,800
Closed -$2.54M – 746
2021
Q2 		$2.54M Hold
13,800
– – 0.02% 385
2021
Q1 		$2.11M Hold
13,800
– – 0.02% 402
2020
Q4 		$2.15M Sell
13,800
-7,900
-36% -$1.02M 0.02% 372
2020
Q3 		$2.48M Hold
21,700
– – 0.02% 326
2020
Q2 		$2.43M Buy
+21,700
New +$2.3M 0.03% 318

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

USS Investment Management's ALXN Position: Q3 2021 in Review

USS Investment Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 13,800 shares — an estimated $2.54M sold.

USS Investment Management first reported a position in ALXN in Q2 2020 and held it in 5 quarters. The position peaked at $2.54M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • USS Investment Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • USS Investment Management sold 13,800 Alexion Pharmaceuticals shares in Q3 2021, an estimated $2.54M.
  • USS Investment Management first reported a position in Alexion Pharmaceuticals in Q2 2020 and held it in 5 quarters.
  • USS Investment Management's Alexion Pharmaceuticals position peaked at $2.54M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on USS Investment Management's 13F filing for Q3 2021, filed 15 Nov 2021.